Durezol

Durezol is a brand name of difluprednate ophthalmic, approved by the FDA in the following formulation(s):

DUREZOL (difluprednate - emulsion; ophthalmic)

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: June 23, 2008
  
  Strength(s): 0.05% ^[RLD]

Has a generic version of Durezol been approved?

No. There is currently no therapeutically equivalent version of Durezol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Durezol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions containing difluprednate
  Patent 6,114,319
  Issued: September 5, 2000
  Inventor(s): Kimura; Masako & Yasueda; Shin-ichi & Yamaguchi; Masazumi & Inada; Katsuhiro
  Assignee(s): Senju Pharmaceutical Co., Ltd.
  Mitsubishi Chemical Corporation
  The present invention relates to a liquid composition comprising difluprednate, oil, water and an emulsifier. The composition of the present invention has superior antiinflammatory action and antiallergic action. The composition of the present invention shows superior transfer to a lesion and uniform drug distribution upon administration, as compared to conventional preparations containing difluprednate, so that it shows sufficient efficacy in a smaller dose. The inventive composition is associated with extremely less uncomfortable feeling and foreign sensation upon administration, as compared to conventional preparations containing difluprednate, and it can be administered easily to local sites of eye, nose, ear and the like.
  
  Patent expiration dates:
  
  
  • May 18, 2019
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 23, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Durezol Consumer Information (Drugs.com)
• Durezol Emulsion Consumer Information (Wolters Kluwer)
• Durezol Consumer Information (Cerner Multum)
• Durezol Advanced Consumer Information (Micromedex)
• Durezol AHFS DI Monographs (ASHP)
• Difluprednate Emulsion Consumer Information (Wolters Kluwer)
• Difluprednate ophthalmic Consumer Information (Cerner Multum)
• Difluprednate Ophthalmic Advanced Consumer Information (Micromedex)
• Difluprednate AHFS DI Monographs (ASHP)